Zai Lab Ltd
ZLAB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ZLAB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZLAB
Zai Lab Ltd is a commercial-stage global biopharmaceutical company with a presence in Greater China and the U.S., focused on discovering, developing, and commercializing therapies in oncology, immunology, neuroscience, and infectious disease [sec_mda · as of 2026-08-06].
Key risk: Clinical trial delays
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 10 clinical trials · 3 catalysts for Zai Lab Ltd.
Zai Lab Ltd is a commercial-stage global biopharmaceutical company with a presence in Greater China and the U.S., focused on discovering, developing, and commercializing therapies in oncology, immunology, neuroscience, and infectious disease [sec_mda · as of 2026-08-06].
- Cash & equivalents of $607.5M, total revenue of $106.3M, net income of -$50.8M, shareholders' equity of $715.5M, and total debt of $238.1M as of 2026-06-30 [sec].
- Pipeline includes global assets such as ZL-1310 (DLL3-targeted ADC for SCLC) and ZL-1311 (MUC17-targeted TCE for gastric/GEJ cancers), and regional assets like povetacicept in IgA nephropathy [sec · filed 2026-04-28] [sec_mda · as of 2026-02-26].
- Achieved NMPA approvals for ZEJULA (first-line maintenance ovarian cancer), VYVGART (gMG), and SUL-DUR (ABC), and NDA acceptance for repotrectinib (ROS1+ NSCLC) [sec · filed 2024-04-29].
- Expects to launch several new products or additional indications for existing commercial products in the next two to three years [sec · filed 2026-04-28].
What works
- Robust pipeline with multiple late-stage assets, including potential first-in-class/best-in-class candidates like ZL-1310 and ZL-1311, supported by internal discovery and business development [sec · filed 2025-04-29] [sec_mda · as of 2026-02-26].
- Commercial-stage presence in both Greater China and the U.S., with a track record of regulatory approvals (e.g., NMPA approvals for ZEJULA, VYVGART, SUL-DUR) [sec · filed 2024-04-29].
- Strong cash position of $607.5M as of 2026-06-30 provides runway to advance pipeline and commercial activities [sec].
- Diversified therapeutic focus across oncology, immunology, neuroscience, and infectious disease reduces single-therapy risk [sec_mda · as of 2026-08-06].
What to weigh
- Net loss of $50.8M for the six months ended June 30, 2026 indicates ongoing unprofitability [sec].
- Some development goals were deprioritized, terminated, or delayed in 2025, reflecting pipeline execution risks [sec · filed 2026-04-28].
- Total debt of $238.1M as of 2026-06-30 adds financial leverage [sec].
- Dependence on regulatory approvals and clinical trial outcomes in competitive therapeutic areas (e.g., SCLC, IgAN) introduces uncertainty [sec · filed 2026-04-28].
From the filings
Quoted directly from source documents.
Company description and focus areas
“We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease.”
SEC MD&A · August 6, 2026
Regulatory achievements in China
“NMPA full approval for ZEJULA as a first-line maintenance treatment for ovarian cancer in China; NMPA approval of VYVGART and acceptance of the sBLA for SC efgartigimod for the treatment of adult patients with gMG in China; NMPA acceptance of NDA for SUL-DUR for ABC; and NMPA acceptance of NDA for repotrectinib for the treatment of ROS1 + NSCLC”
SEC filings · April 29, 2024
Catalyst timeline
- 2026-09-03 · Phase1_Start — Phase 1 start for a randomized, open-label, parallel-group study to evaluate pharmacokinetics, safety, and other endpoints.
- 2028-01-29 · Phase3_Topline — Phase 3 topline data from a multicenter, double-blinded, randomized, placebo-controlled trial to evaluate efficacy.
- 2028-11-30 · Phase3_Topline · zl-1310 — Phase 3 topline data for ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to standard of care.
Risks & what to watch (4)›
Key risks
- Clinical trial delays — Some development goals were deprioritized, terminated, or delayed in 2025 [sec · filed 2026-04-28].
- Regulatory approval uncertainty — Pipeline depends on regulatory approvals in multiple jurisdictions; competitive landscape may affect outcomes [sec · filed 2026-04-28].
- Financial losses — Net loss of $50.8M for H1 2026 indicates ongoing unprofitability [sec].
- Debt burden — Total debt of $238.1M as of 2026-06-30 adds financial leverage [sec].
What to watch
- Phase 1 start for a pipeline candidate on 2026-09-03 [catalyst_timeline].
- Phase 3 topline data for a pipeline candidate on 2028-01-29 [catalyst_timeline].
- Phase 3 topline data for ZL-1310 on 2028-11-30 [catalyst_timeline].
- Progress of povetacicept in IgA nephropathy and primary membranous nephropathy Phase 3/2 studies [sec · filed 2026-04-28].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Zai Lab Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zai Lab Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
33.4 months
D/E 0.77 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
3 upcoming, next in ~4d
2 buys · 36 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
96
Total value held
$487.8M
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 6,574,032 | $123.7M |
| ra capital management, l.p. | 5,707,262 | $107.4M |
| citadel advisors llc | 1,721,832 | $32.4M |
| bamco inc /ny/ | 1,658,318 | $31.2M |
| adar1 capital management, llc | 1,425,367 | $26.8M |
| fmr llc | 1,262,391 | $23.7M |
| blackrock, inc. | 865,146 | $16.3M |
| rock springs capital management lp | 814,707 | $15.3M |
| ubs group ag | 504,191 | $9.5M |
| jane street group, llc | 466,926 | $8.8M |
Showing top 10 of 96 institutional holders of Zai Lab Ltd. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 4.0%
- Days to cover
- 5.5
- Shares short
- 4,453,973
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZLAB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Zai Lab Ltd?
Zai Lab Ltd is a commercial-stage global biopharmaceutical company with a presence in Greater China and the U.S., focused on discovering, developing, and commercializing therapies in oncology, immunology, neuroscience, and infectious disease [sec_mda · as of 2026-08-06].
What is Zai Lab Ltd's next catalyst?
Zai Lab Ltd's next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase 1, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety and" — expected September 3, 2026.
Who is the CEO of Zai Lab Ltd?
Dr. Ying Du Ph.D. is the chief executive officer of Zai Lab Ltd (ZLAB).
Where is Zai Lab Ltd headquartered?
Zai Lab Ltd (ZLAB) is headquartered in Pudong, China.
What therapeutic areas does Zai Lab Ltd focus on?
Zai Lab Ltd develops therapies across Oncology, Immunology, Ophthalmology, Dermatology, Gastroenterology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.